Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology, today reported its financial ...

The company expects next quarter to read out initial data from its Heart-2 trial, which is testing a one-time treatment for people with genetically elevated cholesterol.

The FDA cleared the investigational new drug (IND) application for EVM14. EVM14 is an off-the-shelf tumor-associated antigen ...

Drugs and other treatments can be quite effective at killing cancer cells, yet many fall short as they struggle to penetrate ...

Learn how nanoparticles cross the blood-brain barrier (BBB) and explore their potential in treating neurological disorders through targeted drug delivery.

EVM14 is the first messenger RNA (mRNA) therapeutic vaccine developed internally by the company to gain this approval. Its ...

University of Queensland researchers are designing nanotechnology they believe could improve how we treat the most aggressive form of breast cancer.

EVM14 received U.S. FDA clearance for its IND application, becoming Everest's first internally discovered program, and the first mRNA therapeutic cancer vaccine to be cleared for global clinical ...

Scientists are developing novel nanoparticles that could dramatically increase the effectiveness of immunotherapies when ...

The Kennedy College of Science, Department of Physics, invites you to a Doctoral Dissertation defense by Toby Morris titled, "Novel Methods for Radiation Therapy: Theranostic Nanoparticles and FLASH ...

New magnetic nanoparticles in the shape of a cube sandwiched between two pyramids represent a breakthrough for treating ...

Scalable method rapidly creates stable, flexible carbon nanoparticle films using only water and oil, enabling precise, ...